AU2017246413B2 - cGAS antagonist compounds - Google Patents

cGAS antagonist compounds Download PDF

Info

Publication number
AU2017246413B2
AU2017246413B2 AU2017246413A AU2017246413A AU2017246413B2 AU 2017246413 B2 AU2017246413 B2 AU 2017246413B2 AU 2017246413 A AU2017246413 A AU 2017246413A AU 2017246413 A AU2017246413 A AU 2017246413A AU 2017246413 B2 AU2017246413 B2 AU 2017246413B2
Authority
AU
Australia
Prior art keywords
mmol
compound
mixture
give
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017246413A
Other languages
English (en)
Other versions
AU2017246413A1 (en
Inventor
Chuo Chen
Zhijian Chen
Jing Li
Heping Shi
Lijun Sun
Boyu Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Sensor LLC
The University of Texas System
Original Assignee
Immune Sensor LLC
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Sensor LLC, The University of Texas System, The University of Texas at Austin filed Critical Immune Sensor LLC
Publication of AU2017246413A1 publication Critical patent/AU2017246413A1/en
Priority to AU2021225151A priority Critical patent/AU2021225151B2/en
Application granted granted Critical
Publication of AU2017246413B2 publication Critical patent/AU2017246413B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
AU2017246413A 2016-04-05 2017-04-04 cGAS antagonist compounds Active AU2017246413B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021225151A AU2021225151B2 (en) 2016-04-05 2021-08-31 cGAS ANTAGONIST COMPOUNDS

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662318435P 2016-04-05 2016-04-05
US62/318,435 2016-04-05
US201662355403P 2016-06-28 2016-06-28
US62/355,403 2016-06-28
PCT/US2017/026019 WO2017176812A1 (en) 2016-04-05 2017-04-04 cGAS ANTAGONIST COMPOUNDS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021225151A Division AU2021225151B2 (en) 2016-04-05 2021-08-31 cGAS ANTAGONIST COMPOUNDS

Publications (2)

Publication Number Publication Date
AU2017246413A1 AU2017246413A1 (en) 2018-10-25
AU2017246413B2 true AU2017246413B2 (en) 2021-09-23

Family

ID=60000680

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017246413A Active AU2017246413B2 (en) 2016-04-05 2017-04-04 cGAS antagonist compounds
AU2021225151A Active AU2021225151B2 (en) 2016-04-05 2021-08-31 cGAS ANTAGONIST COMPOUNDS

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021225151A Active AU2021225151B2 (en) 2016-04-05 2021-08-31 cGAS ANTAGONIST COMPOUNDS

Country Status (10)

Country Link
US (4) US10947206B2 (enExample)
EP (1) EP3439667B1 (enExample)
JP (2) JP7116422B2 (enExample)
KR (1) KR102516038B1 (enExample)
CN (1) CN109475565B (enExample)
AU (2) AU2017246413B2 (enExample)
CA (1) CA3020161A1 (enExample)
DK (1) DK3439667T3 (enExample)
ES (1) ES2976118T3 (enExample)
WO (1) WO2017176812A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3439667T3 (da) 2016-04-05 2024-04-02 Immune Sensor Llc Cgas antagonist forbindelser
CN109867648A (zh) * 2017-12-02 2019-06-11 浙江医药股份有限公司新昌制药厂 一种依帕列净有关物质impd的合成方法
MX2020008237A (es) 2018-02-05 2020-09-25 Univ Rockefeller Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
AU2019373407A1 (en) * 2018-11-02 2021-05-20 The Walter And Eliza Hall Institute Of Medical Research Methods of treatment, prevention and diagnosis
WO2020118206A1 (en) * 2018-12-06 2020-06-11 The Scripps Research Institute Butenolide antagonists of the cgas/sting pathway
CN113286785A (zh) * 2019-01-04 2021-08-20 贝尔布鲁克实验室有限责任公司 作为治疗剂的cGAS活性的抑制剂
WO2020186027A1 (en) 2019-03-13 2020-09-17 Daisuke Tomita Inhibitors of cgas for treating autoinflammatory diseases and cancer metastasis
JP2022116370A (ja) * 2019-06-13 2022-08-10 アグロカネショウ株式会社 新規な１－ベンジルアミン誘導体及びこれを有効成分とする農園芸用薬剤
US20230106899A1 (en) 2019-06-21 2023-04-06 Ifm Due, Inc. Methods of treating cancer
CN110305140B (zh) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
KR102895957B1 (ko) * 2020-01-31 2025-12-04 (주)아모레퍼시픽 노화세포 회춘용 조성물 및 노화세포 회춘방법
EP4153304A1 (en) * 2020-05-20 2023-03-29 F. Hoffmann-La Roche AG New malonitrile derivatives
JP2024500877A (ja) * 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
US20240122903A1 (en) 2020-12-22 2024-04-18 Ifm Due Inc. Methods of treating cancer
JP2024500874A (ja) 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
JP2024504002A (ja) * 2020-12-22 2024-01-30 アイエフエム デュー インコーポレイテッド がんを処置する方法
CN112592946A (zh) * 2020-12-31 2021-04-02 河南巨龙生物工程股份有限公司 一种环保型高产鸟苷的工艺方法
CN113651810B (zh) * 2021-07-16 2023-10-13 上海毕得医药科技股份有限公司 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法
CN115073382A (zh) * 2022-07-18 2022-09-20 乐威医药（江苏）股份有限公司 2-氯-嘧啶-5-甲醛的制备方法
EP4638446A1 (en) * 2022-12-20 2025-10-29 Ventus Therapeutics U.S., Inc. Thiadiazole derivatives as inhibitors of cyclic gmp-amp synthase and uses thereof
CN121517400A (zh) * 2024-08-13 2026-02-13 中国科学院上海药物研究所 一类cGAS抑制剂、其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343643A2 (en) * 1988-05-25 1989-11-29 Warner-Lambert Company Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents
WO2004024061A2 (en) * 2002-04-30 2004-03-25 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
WO2004028535A1 (en) * 2002-09-26 2004-04-08 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2004054515A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
US9173871B2 (en) * 2008-01-28 2015-11-03 New York University Oxazole and thiazole compounds as beta-catenin modulators and uses thereof
WO2016154255A1 (en) * 2015-03-23 2016-09-29 University Of Miami Inhibitors of the notch transcriptional activation complex and methods for use of the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
CA2080917C (en) 1990-04-27 2001-06-12 Reijo Baeckstroem New pharmacologically active catechol derivatives
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
KR970002228A (ko) * 1995-06-30 1997-01-24 배순훈 전원변동시 냉장고의 운전제어방법
JP2000095770A (ja) 1998-07-22 2000-04-04 Toa Eiyo Ltd Ｎ置換チアゾリジン誘導体及びそれを含有する医薬
WO2003009807A2 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
EP1605967A1 (en) 2003-03-13 2005-12-21 Novo Nordisk A/S Novel nph insulin preparations
CA2540460A1 (en) * 2003-10-28 2005-05-12 Reddy Us Therapeutics, Inc. Heterocyclic compounds and methods of making and using thereof
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EP2222272B1 (en) * 2008-08-07 2012-11-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
CN101361737B (zh) 2008-09-28 2011-08-03 四川大学 5-苯亚甲基-2，4-噻唑烷二酮衍生物的用途
EP2383263B1 (en) 2008-12-30 2014-04-16 Industry-academic Cooperation Foundation, Chosun University Novel thiazolidinedione derivative and use thereof
KR20100097939A (ko) * 2009-02-27 2010-09-06 연세대학교 산학협력단 신규 ｃｋ2 저해제 및 그의 제조 방법
US9174951B2 (en) * 2012-03-28 2015-11-03 Ohio State Innovation Foundation Glucose transporter inhibitors
WO2014024897A1 (ja) 2012-08-06 2014-02-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 チアゾリジンジオンおよびピロリジンジオン誘導体、並びにそれらを有効成分としてなる殺菌剤
JP2016506408A (ja) 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
JP2016524593A (ja) * 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
EP3164411B1 (en) * 2014-07-04 2019-08-28 Paris Sciences et Lettres - Quartier Latin Fluorogen activating and shifting tag (fast)
DK3439667T3 (da) 2016-04-05 2024-04-02 Immune Sensor Llc Cgas antagonist forbindelser
CN108825600B (zh) 2018-06-15 2021-02-19 上海卫星工程研究所 一种应用于航天器钢丝构件无外力安装装置

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343643A2 (en) * 1988-05-25 1989-11-29 Warner-Lambert Company Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents
WO2004024061A2 (en) * 2002-04-30 2004-03-25 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
WO2004028535A1 (en) * 2002-09-26 2004-04-08 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2004054515A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
US9173871B2 (en) * 2008-01-28 2015-11-03 New York University Oxazole and thiazole compounds as beta-catenin modulators and uses thereof
WO2016154255A1 (en) * 2015-03-23 2016-09-29 University Of Miami Inhibitors of the notch transcriptional activation complex and methods for use of the same

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
Carroll, R. T., ‘Structure–activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B’ Bioorganic & Medicinal Chemistry Letters (2011), 21(16), 4798-4803 *
CAS Registry No. 1262776-15-7; STN Entry date 14 Feb 2011; 3-thiazolidineacetic acid, 5-[(2,3-dibromo-5-ethoxy-4-hydroxyphenyl)methylene]-2,4-dioxo- *
CAS Registry No. 1311116-64-9; STN Entry date 1 Jul 2011; 3-thiazolidineacetic acid, 5-[(2-bromo-5-ethoxy-4-hydroxyphenyl)methylene]-2,4-dioxo-, 1-methylethyl ester *
CAS Registry No. 1311133-35-3; STN Entry date 1 Jul 2011; 3-thiazolidineacetic acid, 5-[(2,3-dibromo-5-ethoxy-4-hydroxyphenyl)methylene]-2,4-dioxo-, 1-methylethyl ester *
CAS Registry No. 365978-56-9; STN Entry date 1 Nov 2001; 2,4-Thiazolidinedione, 5-[(2-bromo-5-ethoxy-4-methoxyphenyl)methylene]-3-methyl- *
CAS Registry No. 365987-75-3; STN Entry date 1 Nov 2001; 2,4-Thiazolidinedione, 5-[(2-bromo-5-ethoxy-4-methoxyphenyl)methylene]-3-methyl- *
CAS Registry No. 365992-07-0; STN Entry date 1 Nov 2001; 2,4-Thiazolidinedione, 5-[(2-bromo-4,5-diethoxyphenyl)methylene]-3-methyl- *
CAS Registry No. 366459-31-6; STN Entry date 2 Nov 2001; Acetic acid, 2-[5-bromo-2-ethoxy-4-[(3-methyl-2,4-dioxo-5-thiazolidinylidene)methyl]phenoxy]-, methyl ester *
CAS Registry No. 366460-16-4; STN Entry date 2 Nov 2001; Acetic acid, 2-[5-bromo-2-methoxy-4-[(3-methyl-2,4-dioxo-5-thiazolidinylidene)methyl]phenoxy]-, ethyl ester *
CAS Registry No. 366473-39-4; STN Entry date 2 Nov 2001; Acetic acid, 2-[5-bromo-2-methoxy-4-[(3-methyl-2,4-dioxo-5-thiazolidinylidene)methyl]phenoxy]-, methyl ester *
CAS Registry No. 366483-10-5; STN Entry date 2 Nov 2001; Acetic acid, 2-[5-bromo-2-ethoxy-4-[(3-methyl-2,4-dioxo-5-thiazolidinylidene)methyl]phenoxy]-, ethyl ester *
CAS Registry No. 366485-36-1; STN Entry date 2 Nov 2001; 2,4-Thiazolidinedione, 5-[[4-(acetyloxy)-2-bromo-5-methoxyphenyl]methylene]-3-methyl- *
CAS Registry No. 366820-57-7; STN Entry date 5 Nov 2001; 2,4-Thiazolidinedione, 5-[(2,3-dibromo-4-hydroxy-5-methoxyphenyl)methylene]-3-methyl- *
CAS Registry No. 366826-35-9; STN Entry date 5 Nov 2001; Acetic acid, 2-[5-bromo-2-ethoxy-4-[(3-methyl-2,4-dioxo-5-thiazolidinylidene)methyl]phenoxy]- *
CAS Registry No. 367454-14-6; STN Entry date 7 Nov 2001; 2,4-Thiazolidinedione, 5-[(2-bromo-4,5-dimethoxyphenyl)methylene]-3-methyl- *
CAS Registry No. 367455-53-6; STN Entry date 7 Nov 2001; 2,4-Thiazolidinedione, 5-[(2-bromo-4-ethoxy-5-methoxyphenyl)methylene]-3-methyl- *
CAS Registry No. 402588-65-2; STN Entry date 22 Mar 2002; 2,4-Thiazolidinedione, 5-[(2-chloro-4,5-dimethoxyphenyl)methylene]-3-methyl- *
CAS Registry No. 664351-91-1; STN Entry date 18 Mar 2004; acetic acid, 2-[5-bromo-2-ethoxy-4-[[3-(1-methylpropyl)-2,4-dioxo-5-thiazolidinylidene]methyl]phenoxy]- *
CAS Registry No. 664357-46-4; STN Entry date 18 Mar 2004; 2,4-thiazolidinedione, 5-[(2-bromo-5-ethoxy-4-hydroxyphenyl)methylene]-3-ethyl- *
CAS Registry No. 664359-14-2; STN Entry date 18 Mar 2004; 2,4-thiazolidinedione, 5-[(2-chloro-5-ethoxy-4-methoxyphenyl)methylene]-3-ethyl- *
CAS Registry No. 664360-06-9; STN Entry date 18 Mar 2004; acetic acid, 2-[5-bromo-2-ethoxy-4-[(3-ethyl-2,4-dioxo-5-thiazolidinylidene)methyl]phenoxy]-, ethyl ester *
CAS Registry No. 675168-01-1; STN Entry date 14 Apr 2004; 2,4-thiazolidinedione, 3-butyl-5-[(2-chloro-4,5-dimethoxyphenyl)methylene]- *
CAS Registry No. 675168-13-5; STN Entry date 14 Apr 2004; 2,4-Thiazolidinedione, 5-[(2-bromo-4-ethoxy-5-methoxyphenyl)methylene]-3-butyl- *
CAS Registry No. 675192-26-4; STN Entry date 14 Apr 2004; acetic acid, 2-[5-bromo-4-[(3-butyl-2,4-dioxo-5-thiazolidinylidene)methyl]-2-methoxyphenoxy]-, methyl ester *
CAS Registry No. 677312-58-2; STN Entry date 28 Apr 2004; 2,4-thiazolidinedione, 5-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylene]-3-(2-methoxyethyl)- *
CAS Registry No.: 1164525-75-0; Date entered STN 19 July 2009; 5-[(2-bromo-5-ethoxy-4-hydroxyphenyl)methylene]-3-ethyl-2-(ethylimino)- 4-thiazolidinone *
CAS Registry No.: 1311133-35-3; Date entered STN 1 July 2011; -methylethyl 5-[(2,3-dibromo-5-ethoxy-4-hydroxyphenyl)methylene]-2,4-dioxo-3-thiazolidineacetate *
CAS Registry No.: 1321893-65-5; Date entered STN 23 August 2011; 2-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylene]benzo[b]thiophen-3(2H)-one *
CAS Registry No.: 641603-77-2; Date entered STN 26 January 2004; 5-[(2-Bromo-4-ethoxy-5-methoxyphenyl)methylene]-3-ethyl-2,4-imidazolidinedione *
CAS Registry No.: 897508-44-0; Date entered STN 31 July 2006; 5-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylene]-3-(3-methoxypropyl)-2-thioxo-4-imidazolidinone *
Georgescu, R. E., et al., 'Structure of a small-molecule inhibitor of a DNA polymerase sliding clamp', PNAS, 2008, 105(32), 11116-11121 *
PUBCHEM. CID 97857. 26 March 2005, pp. 1-15. Retrieved from the Internet <URL:https://pubchem.ncbi.nlm.nih.gov/compound/97857> *
Raouf, A. R. A., et al., 'Studies on 4-thiazolidinones, IV', Acta Chimica Academiae Scientiarum Hungaricae, 1975, 87(2), 187-93 *
SHIBNATH G. ET AL, "Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors...", Bioorg. Med Chem Lett., 2014 vol. 24, no. 1, pages 317-324 *
Swathi, T. et al ‘Green condensation reaction of aromatic aldehydes with rhodanine catalyzed by alum under microwave irradiation’, Pharma Chemica (2015), 7(3), 100-104 *
Zelisko, N. et al, ‘Synthesis of fused thiopyrano[2,3-d][1,3]thiazoles via hetero-Diels Alder reaction related tandem and domino processes’, Tetrahedron (2015), 71(50), 9501-9508 *

Also Published As

Publication number Publication date
US10947206B2 (en) 2021-03-16
EP3439667B1 (en) 2024-01-03
CA3020161A1 (en) 2017-10-12
US20180230115A1 (en) 2018-08-16
EP3439667A4 (en) 2019-10-30
WO2017176812A1 (en) 2017-10-12
JP7116422B2 (ja) 2022-08-10
US12065416B2 (en) 2024-08-20
AU2021225151B2 (en) 2023-07-27
DK3439667T3 (da) 2024-04-02
US20220356158A1 (en) 2022-11-10
JP2019510787A (ja) 2019-04-18
AU2021225151A1 (en) 2021-09-30
US20240043393A1 (en) 2024-02-08
CN109475565A (zh) 2019-03-15
AU2017246413A1 (en) 2018-10-25
US11597707B2 (en) 2023-03-07
KR20190018620A (ko) 2019-02-25
CN109475565B (zh) 2021-11-02
KR102516038B1 (ko) 2023-03-31
US20250115564A1 (en) 2025-04-10
JP7530068B2 (ja) 2024-08-07
US12655118B2 (en) 2026-06-16
ES2976118T3 (es) 2024-07-23
JP2022105091A (ja) 2022-07-12
EP3439667A1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
AU2021225151B2 (en) cGAS ANTAGONIST COMPOUNDS
US11541050B2 (en) Pyrimidine derivatives for the treatment of viral infections
AU2018256459B2 (en) Indole AHR inhibitors and uses thereof
US20250376473A1 (en) Prmts inhibitor and use thereof
US20240400560A1 (en) Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
UA82435C2 (uk) Конденсовані гетероциклічні сполуки та їх застосування як метаботропних антагоністів рецепторів глутамату, фармацевтична композиція на їх основі
US12091387B2 (en) Quinoline cGAS antagonist compounds
US20250154105A1 (en) Polycyclic compound and use thereof
CA2938476A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
WO2020140894A1 (zh) 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
EA052757B1 (ru) Полициклическое соединение и его применение
HK40004439B (en) Cgas antagonist compounds
HK40004439A (en) Cgas antagonist compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)